CVRx, Inc. announced on November 4, 2024, that the Centers for Medicare and Medicaid Services (CMS) has assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. This assignment ensures an associated payment of approximately $45,000 for procedures performed in the outpatient setting, which will continue throughout 2025.
This decision was published in the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. The continuation of this payment level is a positive development for CVRx, as it provides clarity and stability for healthcare providers.
The consistent reimbursement rate is expected to support broader market adoption and long-term growth for Barostim. It follows previous positive developments, including the reassignment of Barostim to a higher-paying MS-DRG for inpatient procedures effective October 1, 2024, and the acceptance of Category I CPT codes for physician payments starting January 1, 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.